1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Cardiovascular Diseases in 10 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Fasudil, a selective Rho-kinase inhibitor developed in Japan, is effective for the treatment of a wide range of cardiovascular diseases, with reasonable safety." | 4.84 | Progress of the study of rho-kinase and future perspective of the inhibitor. ( Shimokawa, H; Tawara, S, 2007) |
| "We evaluated the ratio of phospho myosin-binding subunit (p-MBS) on myosin light-chain phosphatase to total MBS in peripheral leukocytes by Western blot analysis and forearm blood flow (FBF) response to the ROCK inhibitor fasudil using strain-gauge plethysmography in 36 healthy subjects and 39 patients with cardiovascular diseases." | 3.77 | Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. ( Chayama, K; Fujii, Y; Fujimura, N; Goto, C; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J, 2011) |
| "Cardiovascular diseases are associated with chronic activation of Rho-associated kinases (ROCKs) and endothelial dysfunction." | 1.37 | Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. ( Chayama, K; Fujii, Y; Fujimura, N; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Kato, H; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, J | 2 |
| Wei, L | 2 |
| Lu, Q | 1 |
| Longo, FM | 1 |
| Zhou, H | 1 |
| Massa, SM | 1 |
| Chen, YH | 1 |
| Hata, T | 2 |
| Goto, C | 1 |
| Soga, J | 2 |
| Hidaka, T | 2 |
| Fujii, Y | 2 |
| Idei, N | 2 |
| Fujimura, N | 2 |
| Maruhashi, T | 2 |
| Mikami, S | 2 |
| Kihara, Y | 2 |
| Chayama, K | 2 |
| Noma, K | 2 |
| Liao, JK | 2 |
| Higashi, Y | 2 |
| Kato, H | 1 |
| Surma, M | 1 |
| Mukai, Y | 1 |
| Tawara, S | 1 |
| Shimokawa, H | 2 |
| Duan, WG | 1 |
| Yuan, ST | 1 |
| Liao, H | 1 |
| Yan, M | 1 |
| Zhang, LY | 1 |
| Okada, M | 1 |
| Hojo, Y | 1 |
| Ikeda, U | 1 |
| Takahashi, M | 1 |
| Takizawa, T | 1 |
| Morishita, R | 1 |
| Shimada, K | 1 |
5 reviews available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Cardiovascular Diseases
| Article | Year |
|---|---|
Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cardiovascular Diseases; Cardiovascu | 2013 |
Rho kinase as a therapeutic target in cardiovascular disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Apoptosis; Cardiovascular Diseases; Coronary | 2011 |
Progress of the study of rho-kinase and future perspective of the inhibitor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiovascular Diseases; Cell Proliferation; | 2007 |
[Advances in the study of Rho kinase and its inhibitors].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Antihypertensive Agents; Cardiovascular Disea | 2007 |
Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cardiovascular Diseases; Coronary Ve | 2002 |
5 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Cardiovascular Diseases
| Article | Year |
|---|---|
Signaling through Rho GTPase pathway as viable drug target.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Aminoquinolines; Anilides; Animals; Benzamide | 2009 |
Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Atherosclerosis; Blood Flow Velocity; Ca | 2011 |
Rho-associated kinase activity, endothelial function, and cardiovascular risk factors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Blood Pressure; Blotting, Western; Body | 2011 |
[Involvement of Rho-kinase in hypertensive vascular disease--a novel therapeutic target in hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Vessels; Cardiovascular Diseases; Hype | 2002 |
Interaction between monocytes and vascular smooth muscle cells induces expression of hepatocyte growth factor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antibodies, Monoclonal; Cardiovascular Diseases; Cell | 2000 |